60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP - Get Free Report) CEO Geoffrey S. Dow purchased 17,549 shares of the company's stock in a transaction that occurred on Thursday, December 5th. The shares were purchased at an average cost of $1.11 per share, with a total value of $19,479.39. Following the completion of the purchase, the chief executive officer now owns 38,178 shares in the company, valued at $42,377.58. This trade represents a 85.07 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.
60 Degrees Pharmaceuticals Stock Performance
Shares of SXTP stock opened at $1.45 on Tuesday. The stock has a 50 day moving average price of $1.00 and a 200 day moving average price of $0.81. 60 Degrees Pharmaceuticals, Inc. has a 52-week low of $0.70 and a 52-week high of $18.36. The firm has a market capitalization of $3.34 million, a P/E ratio of -0.14 and a beta of 5.36.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "neutral" rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, November 15th.
View Our Latest Report on SXTP
60 Degrees Pharmaceuticals Company Profile
(
Get Free Report)
Forbes rich list released… #1 to be assassinated?
From Porter & Company | Ad
Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X.
And people are slowly starting to wake up to the Deep State’s lies.
To get the full details on the fake “energy crisis” of America, watch this now
60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
